Additionally, recent research indicates the presence of tumor-infiltrating lymphocytes in SCLC patients without detectable PDL1 expression [25], suggesting the potential clinical role of alternative immune checkpoints in the tumor microenvironment. This evidence concerns the gene CD274 and neoplasm.